Short Interest in Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Expands By 1,180.0%

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) saw a significant growth in short interest in March. As of March 31st, there was short interest totalling 6,400 shares, a growth of 1,180.0% from the March 15th total of 500 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average trading volume of 866,800 shares, the short-interest ratio is currently 0.0 days.

Provectus Biopharmaceuticals Trading Up 3.0 %

Shares of Provectus Biopharmaceuticals stock traded up $0.00 during trading on Monday, reaching $0.10. 31,218 shares of the stock traded hands, compared to its average volume of 227,284. The business has a fifty day simple moving average of $0.10 and a two-hundred day simple moving average of $0.11. Provectus Biopharmaceuticals has a 52-week low of $0.04 and a 52-week high of $0.20.

About Provectus Biopharmaceuticals

Provectus Biopharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis.